Giuseppe Del Priore

Grady Health System — United States

Medicine · Health Sciences

27h-index3.0kcitations300works1.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Endometrial and Cervical Cancer Treatments(50), Organ and Tissue Transplantation Research(42), Ovarian cancer diagnosis and treatment(36), Cancer Risks and Factors(25), Cervical Cancer and HPV Research(21)

Publications300 total

WITHDRAWN: 655eTiP Phase III pivotal trial of Bria-IMT + CPI vs physician’s choice in advanced metastatic breast cancer (BRIA-ABC)
Annals of Oncology·2025
570P Feasibility and biomarker validation of an international randomized phase 3 trial of bria-IMT cell therapy in late stage MBC (Bria-ABC)
Annals of Oncology·2025
Abstract P5-10-12: Bria-IMT CD8+ Tumor Infiltrating Lymphocytes Turn “Cold” Tumor “Hot” in Metastatic Breast Cancer
Clinical Cancer Research·2025
Abstract P1-01-17: PD-L1 Upregulation in Circulating Tumor Associated Cells Predicts for clinical outcomes in a phase I/II clinical trial using SV-BR-1-GM vaccine with the check point inhibitor retifanlimab in Metastatic Breast Cancer Patients, an Interim Analysis
Clinical Cancer Research·2025
Abstract PS3-04: Overall Survival Results of Bria-IMT Allogenic Whole Cell-Based Cancer Vaccine
Clinical Cancer Research·2025
Abstract P2-10-24: ASTRO-VAC CNS : Bria-IMT in the Management of Tumor Agnostic Metastatic CNS Lesions
Clinical Cancer Research·2025
Impact of HLA matching on clinical outcomes in a phase 2 trial of Bria-IMT plus anti PD1 in advanced breast cancer.
Journal of Clinical Oncology·2025
Bria-IMT + checkpoint inhibitor: Phase I/II survival results compared to benchmark trials in metastatic breast cancer.
Journal of Clinical Oncology·2025· 1 cited
Update on phase III pivotal trial of Bria-IMT + CPI vs physician’s choice in advanced metastatic breast cancer (BRIA-ABC).
Journal of Clinical Oncology·2025
Abstract CT100: Survival outcomes in a randomized phase 2 of<i>Bria-IMT</i>: An allogeneic whole cell cancer vaccine
Cancer Research·2025
Abstract LB408: <i>Bria-</i>ABC vs physician choice in late stage MBC: Early biomarker correlates of the randomized registration trial
Cancer Research·2025
Inequities in Surgical Access for Women With Endometrial Cancer in the United States: Opportunities for Surgical Justice
The American Surgeon·2025· 1 citedOpen Access
Screening for endometrial disease: Analyzing risk factors for abnormal endometrial pathology in a high-risk population
Gynecologic Oncology·2024
Results of a phase I/IIa trial of SV-BR-1-GM inoculation with low-dose cyclophosphamide and interferon alpha (Bria-IMT) in metastatic breast cancer
Human Vaccines & Immunotherapeutics·2024· 6 citedOpen Access
SV-BR-1-GM after progression on ADC in patients with metastatic breast cancer.
Journal of Clinical Oncology·2024
Outcomes of advanced/metastatic breast cancer (aMBC) treated with BRIA-IMT, an allogeneic whole cell immunotherapy.
Journal of Clinical Oncology·2024· 1 cited
Study of the Bria-IMT regimen and CPI vs physicians' choice in advanced metastatic breast cancer (BRIA-ABC).
Journal of Clinical Oncology·2024· 1 cited
Differential efficacy of SV-BR-1-GM in inducing intracranial metastasis regression.
Journal of Clinical Oncology·2024
Abstract PO1-20-12: CD8+ Tumor Infiltrating Lymphocytes Turn a Cold Tumor Hot in Metastatic Breast Cancer
Cancer Research·2024
Abstract PO2-13-06: Analysis of Antibody Response to SV-BR-1-GM Therapeutic Vaccine in Breast Cancer Patients Using Human Protein Microarrays: Potential Correlations with Therapy Response
Cancer Research·2024· 1 cited
page 1 of 15Next →

Frequent Co-authors

László Ungár(15), Jr. Smith(14), James R. Smith(10), D. Corless(10), Srdjan Saso(9), Sadaf Ghaem‐Maghami(7), Iain Lindsay(6), Krishen Sieunarine(6), László Pálfalvi(4), David E. Noakes(4), Jayanta Chatterjee(4), Michael Boyd(4), Deborah C.M. Boyle(3), Ali Hassan Hamed(3), Meen-Yau Thum(3), Gemma Petts(3), Anna L. David(3), D. Noakes(3), Allan S. Klapper(3), Andrew Lawson(2)